Chapter category: Neurodegenerative Disease
APP α -Secretase, a Novel Target for Alzheimer Drug Therapy
Ab Metabolism and Alzheimer's Disease
Edited by: Takaomi SaidoISBN: 1-58706-230-5
» Get more information about this book at landesbioscience.com «
Chapter authors:
Shoichi Ishiura, Masashi Asai, Chinatsu Hattori, Nika Hotoda, Beata Szabo, Noboru Sasagawa and Sei-ichi Tanuma
The neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β peptide (Aβ) in plaques in brain tissue (amyloid hypothesis). Mechanisms of Aβ production in the brain have been the subject of considerable interest. Several factors regulate processing of amyloid precursor protein (APP), which is cleaved by three types of membrane-bound proteases designated α- β- and γ-secretases. Although we are only beginning to understand their functions, the discovery of nonamyloidogenic α—secretase has already provided some answers to longstanding questions of Alzheimer drug development. Here we summarize recent advances in the identification of APP α-secretases. Pharmacological upregulation γ-secretases should provide rational drug design for Alzheimer's disease.
Additional chapters from this book:
Modulating Amyloid-β Levels by Immunotherapy: A Potential Therapeutic
Cynthia A. Lemere, Timothy J. Seabrook, Melitza Iglesias, Chica Mori, Jodi F. Leverone and Edward T. Spooner
Alzheimer's disease (AD) is the most common form of dementia and afflicts ~15-20 million people worldwide. Currently, there is no effective cure. Research efforts over the past decade have dem...
Potential Role of Endogenous and Exogenous Aβ Binding Molecules in Aβ Clearance and Metabolism
Donald B. DeMattos, Kelly R. Bales, Steven M. Paul and David M. Holtzman
Alzheimer's disease (AD) is the leading cause of dementia in the elderly and there are currently no effective therapies for either the prevention or treatment of this disease. The last decade ...
Transport-Clearance Hypothesis for Alzheimer's Disease and Potential Therapeutic
Berislav V. Zlokovic and Blas Frangione
Alzheimer's disease (AD) is the major cause of dementia and the most common form of human amyloidosis. AD affects an astoundingly large number of people and is common with advancing age. The b...
Amyloid β-Protein in Low-Density Membrane Domains
Maho Morishima-Kawashima and Yasuo lhara
Membrane microdomains, which have just been emerging thanks to recent technological progress, may have significant roles in normal cell functions such as adhesion, signaling, and trafficking. ...
Aβ Metabolism in Cholesterol Enriched Membrane Microdomains
Todd E. Golde and M. Paul Murphy
Aggregation and accumulation of Aβ is a pathological hallmark of the Alzheimer's disease (AD) brain. Studies on cerebrospinal fluid (CSF) from living patients and postmortem control brain...
Aβ Degradation by Endothelin-Converting Enzymes
Elizabeth A. Eckman and Christopher B. Eckman
The abnormal accumulation of β-amyloidloid (Aβ) in the brain is an early and invariant feature of Alzheimer's disease and is believed to play a pivotal role in the etiology and patho...
Proteolytic Degradation of Aβ by Neprilysin and Other Peptidases
Takaomi C. Saido and Hiroyuki Nakahara
Amyloid β peptide (Aβ), the pathogenic agent of Alzheimer's disease (AD), is a physiological metabolite in the brain. We focused our attention and effort on elucidation of the unreso...
Functional Roles of APP Secretases
Cleavage of APP by α-, β and γ-secretases strikingly resembles regulated intramembrane proteolysis (RIP), which is normally employed to generate signaltransducing fragments f...
γ -Secretase and Presenilin
Michael S. Wolfe
Because production and deposition of the amyloid-β peptide (Aβ) is intimately linked to the pathogenesis of Alzheimer's disease (AD), the proteases responsible for excising Aβ f...
APP α -Secretase, a Novel Target for Alzheimer Drug Therapy
Shoichi Ishiura, Masashi Asai, Chinatsu Hattori, Nika Hotoda, Beata Szabo, Noboru Sasagawa and Sei-ichi Tanuma
The neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β peptide (Aβ) in plaques in brain tissue (amyloid hypothesis). Mechanisms of Aβ production ...
β - Secretase: Progress and Open Questions
Martin Citron
Finding inhibitors of Aβ42 generation is a major goal of Alzheimer's disease drug development. Two target protease activities, β-and γ-secretases, were operationally defined mo...
Overview - Aβ Metabolism: From Alzheimer
Takaomi C. Saido
Readers and authors of this book alike are the allies of scientists and scientists-to-be in the fight against one of our most common and mightiest enemies, Alzheimer's disease (AD), which depr...
